WW WW International Inc.

Labcorp Elevates Employee Health Benefits with WeightWatchers for Business Full-Spectrum Weight Health Platform

Labcorp Elevates Employee Health Benefits with WeightWatchers for Business Full-Spectrum Weight Health Platform

NEW YORK and BURLINGTON, N.C., Feb. 07, 2024 (GLOBE NEWSWIRE) -- WeightWatchers (NASDAQ: WW), (“WeightWatchers,” “WW,” or the “Company”) today announced that Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, is deepening its existing partnership with to offer their full-spectrum weight health platform, with individualized pathways of both behavioral and clinical interventions, available at no cost to Labcorp’s U.S. employees. Spouses and domestic partners covered under a Labcorp medical plan are also eligible.

WeightWatchers for Business is the complete weight health platform designed for employers, payers, and health plans, providing science-proven behavior change programs, access to virtual clinic care, and medication management for those eligible.

“We’ve had a long-standing collaboration with WeightWatchers for Business, and we’re excited to expand on that partnership with this new comprehensive offering for our employees,” said Brian Caveney, M.D., Chief Medical and Scientific Officer, Labcorp. “From implementation to client management, WeightWatchers for Business makes it easy for Labcorp to offer our employees some of the best, most streamlined, and easy-to-navigate programs to meet and sustain their weight health goals.”

For nearly a decade, Labcorp has been a valued client of WeightWatchers for Business, incorporating its behavioral program into its benefits offerings. Building on the existing partnership, Labcorp and WeightWatchers for Business will expand this benefit to offer a full-spectrum weight health platform for Labcorp employees and their eligible spouses and domestic partners. This comprehensive approach delivers individualized pathways based on clinical need and is designed to optimize both the experience and outcomes for members. The result is an end-to-end solution covering everything from behavioral programs to access to clinical evaluations and treatment options, as well as medication management for those eligible and in need of a high-touch solution. Highlights of the program include:

  • WeightWatchers’ science-backed behavior-change programs for sustained outcomes - including the #1 doctor-recommended Points Program,1 as well as weight management programs tailored to those living with diabetes and those on GLP-1 medications.
  • Access to virtual clinic care and medication management for those eligible, including GLP-1s, when appropriate, under the guidance of board-certified clinicians as well as registered dietitians, fitness specialists, and care coordinators.
  • Robust virtual and real-life community coaching support at scale and integrated health insights.

“Labcorp and WeightWatchers for Business share a philosophy of opening access to a full spectrum of clinically proven weight health tools and resources,” said Amy Meister, D.O., Chief Medical Officer, WeightWatchers. “Implementing this comprehensive program reflects Labcorp’s commitment to their employees to ensure they have the holistic support they need to achieve sustained health outcomes.”

About WW International, Inc.

WeightWatchers is a human-centric technology company powered by our proven, science-based, clinically effective weight loss and weight management programs. For six decades, we have inspired millions of people to adopt healthy habits for real life. We combine technology and community to help members reach and sustain their goals on our programs. To learn more about the WeightWatchers approach to healthy living, please visit ww.com. For more information about our global business, visit our corporate website at corporate.ww.com.

About Labcorp

Labcorp (NYSE: LH) is a global leader of innovative and comprehensive laboratory services that helps doctors, hospitals, pharmaceutical companies, researchers and patients make clear and confident decisions. We provide insights and advance science to improve health and improve lives through our unparalleled diagnostics and drug development laboratory capabilities. The company's more than 60,000 employees serve clients in over 100 countries, worked on over 80% of the new drugs approved by the FDA in 2022 and performed more than 600 million tests for patients around the world. Learn more about us at .

1 Based on a 2020 IQVIA survey of 14,000 doctors who recommend weight-loss programs to patients.



For more information, contact:

Media:
Kelsey Merkel
 
EN
07/02/2024

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on WW International Inc.

 PRESS RELEASE

CheqUp and WeightWatchers Announce Strategic Partnership to Support Gr...

CheqUp and WeightWatchers Announce Strategic Partnership to Support Growing Use of GLP-1 Medications in the UK Partnership Provides CheqUp Members Access to WeightWatchers’ Proven GLP-1 Companion Programme to Aid in Achieving Superior and Sustainable Results CHIPPENHAM, England, May 22, 2025 (GLOBE NEWSWIRE) -- , one of the UK’s leading providers of GLP-1 based weight loss services, and , the global leader in science-backed weight management, have announced a partnership that will combine the offerings of both organizations to benefit patients seeking sustainable weight loss through GLP...

 PRESS RELEASE

WeightWatchers Takes Strategic Action to Eliminate $1.15 Billion of De...

WeightWatchers Takes Strategic Action to Eliminate $1.15 Billion of Debt, Strengthening Financial Position for Long-Term Growth and Profitability Operations continue with no impact to its more than three million members worldwide Positions the Company to execute its transformation strategy, focused on enhancing its digital and member experience and expanding its telehealth business which achieved 57% year-over-year revenue growth in Q1 2025 Enters comprehensive agreement with lenders and noteholders to significantly reduce its debt obligations and bolster financial flexibility ...

 PRESS RELEASE

WW International, Inc. Schedules Investor Conference Call

WW International, Inc. Schedules Investor Conference Call NEW YORK, May 06, 2025 (GLOBE NEWSWIRE) -- WW International, Inc. (NASDAQ: WW) (“WeightWatchers” or the “Company”), the global leader in science-backed weight management, announced that it will host an investor conference call today May 6, 2025, at 6:00 p.m. ET. During the call, Tara Comonte, President and Chief Executive Officer, and Felicia DellaFortuna, Chief Financial Officer, will discuss an agreement with the Company’s lenders and noteholders that will significantly reduce debt obligations that is currently expected to result...

 PRESS RELEASE

WW International, Inc. Announces First Quarter 2025 Results

WW International, Inc. Announces First Quarter 2025 Results Total End of Period Subscribers of 3.4 million, including 135 thousand End of Period Clinical SubscribersRevenues of $186.6 million, down 9.7% vs. prior year period, including Clinical Subscription Revenues of $29.5 million, up 57.1% vs. prior year periodSubscription Revenues Per Paid Weeks up 4.8% vs. prior year periodGross Margin of 71.2%, up 450 basis points vs. prior year period; Adjusted Gross Margin of 71.0%, up 311 basis points vs. prior year periodNet Loss of $72.6 million; Net Loss Margin of 38.9%, improved from Net Loss M...

 PRESS RELEASE

WeightWatchers Streamlines Member Access to Zepbound® Vials with Lilly...

WeightWatchers Streamlines Member Access to Zepbound® Vials with LillyDirect® Pharmacy Provider New Integration with Gifthealth Simplifies Fulfillment and Medication Visibility for WeightWatchers Clinic Members NEW YORK, April 29, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: WW) (“WeightWatchers,” “WW,” or the “Company”), the global leader in science-backed weight management, today announced a pharmacy integration with Eli Lilly and Company’s LillyDirect® pharmacy provider, . The integration will streamline access to Lilly’s FDA-approved Zepbound® (tirzepatide) single-dose vials for WeightWatcher...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch